HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
A better way to predict long-term stock returns
stocks
Five star stock added to August best ideas list
stocks
Undervalued supermarket share sees sales improvement
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,927.30 | 7.10 | 0.08% |
| CAC 40 | 8,179.77 | 63.01 | 0.78% |
| DAX 40 | 25,568.56 | 207.41 | 0.82% |
| Dow JONES (US) | 52,573.29 | 509.19 | 0.98% |
| FTSE 100 | 10,650.44 | 41.52 | 0.39% |
| HKSE | 24,721.55 | 84.08 | -0.34% |
| NASDAQ | 26,333.04 | 251.31 | 0.96% |
| Nikkei 225 | 63,395.35 | 615.99 | -0.96% |
| NZX 50 Index | 13,654.76 | 74.43 | 0.55% |
| S&P 500 | 7,656.98 | 65.28 | 0.86% |
| S&P/ASX 200 | 8,749.60 | 8.40 | 0.10% |
| SSE Composite Index | 3,878.60 | 9.51 | -0.24% |